Research Management. 4.1. The Charity expects that all Research will be conducted according to the highest standards of rigor and integrity and to all applicable codes of practice.
4.2. The Host Institution must have measures in place to mitigate the risk of incidences of scientific misconduct and must inform the Charity, in confidence and at the earliest opportunity, of any allegations of fraud or other misconduct and of the progress and outcome of any investigations.
4.3. The Charity reserves the right to carry out its own investigation into any allegation of fraud or misconduct and requires the Host Institution to provide such assistance and information as the Charity may reasonably require for that purpose.
4.4. The Host Institution accepts full responsibility for ensuring that all necessary legal and regulatory requirements are met and that any necessary or appropriate ethical approvals are obtained. This includes obtaining all licences and approvals.
4.5. The Host Institution is responsible for managing conflicts of interest and must notify the Charity of any relevant conflicts that may arise. The Host Institution must use all reasonable endeavours to ensure that the Charity is not put at risk of any breach of charity law or other applicable regulation resulting from the relationship of any of the research personnel with a commercial organisation.
Research Management. Ability to successfully identify and secure possible sources of funding for personal and team research as appropriate. Project management skills relating to proposals and tenders work programming, supervision, deadlines and delivery, negotiation with funders, financial planning, and resource management. Skills appropriate to working with others and in teams and in teambuilding.
Research Management. (a) During the term of the Agreement, three or more representatives of each party will be named to serve on the Joint Research Committee (the "JRC"). The JRC shall meet regularly (at least two times per year in person and more frequently at the call of a 11 ***CONFIDENTIAL TREATMENT REQUESTED representative from either party face to face, by telephone or video conferencing) to oversee the progress of the Research. The timing and location of such meetings will be agreed upon by the parties. SGX will provide a written report (the "Progress Report") detailing the progress of the Research quarterly, with the Progress Report scheduled for quarters immediately preceding meetings of the JRC to be distributed to CFFT at least three (3) business days prior to such meetings. Without limitation, SGX will include in the Progress Reports in reasonable detail SGX's interpretation of the data.
(b) The JRC will be responsible for: approving the detailed research plans for the first and subsequent years of the Research and any revision thereto; coordinating and monitoring research progress; determining the numbers of FTE's required to accomplish the tasks specified in the Research Plan, determining the successful completion of Appendix A milestones and Milestone Events; ensuring open and frequent exchanges between the parties with respect to Research activities; and approving priorities of the Research and allocations of tasks and resources required to carry out the goals of the Research. All such decisions will be made by consensus of the JRC; provided however, that CFFT will have the final decision as to the setting of priorities for the Research and with respect to all decisions relating directly or indirectly to payments (including the completion of Appendix A milestones and Milestone Events) under this Agreement. Decisions of the JRC are [...***...].
Research Management. A. The research under each Project will be supervised by the Principal Investigator(s) identified in such Project. No substitution of any such Principal Investigator(s) will be made without the prior written consent of CERES.
B. Each Party acknowledges and agrees that the Projects are research in nature and hence the achievement of the deliverables and/or milestones specified in the Projects cannot be guaranteed. Neither Party guarantees any particular outcome or specific yield arising from any Project.
C. Each Party will require any and all of its employees and researchers who will perform Program activities to sign a statement stating that they have read and understand the obligations of AGRILIFE under Article VI and Article XI. AGRILIFE affirms that, as per The Texas A&M University System Policy 17.01, Subsection 2.2.1, intellectual property conceived or developed with support from TAMUS or any of its members in the form of administered funds shall be owned by TAMUS, and that the funding received from CERES will constitute such administered funds under such policy.
D. Except in the case of permitted subcontracting as provided in Article III.H, below, each Party will conduct Program activities exclusively in laboratories, greenhouses or fields under full control of or owned by that Party. Each Party will take all reasonable precautions to prevent damage to or third party access to any information related to, or unintentional destruction of or release of, any germplasm created in the Program.
E. Each Party will strictly comply, and use its commercially reasonable efforts to cause its employees and researchers conducting Program activities to comply, with notebook and breeding book keeping policies of the highest standards as applicable in the field. Each Party will record and keep all field evaluation, composition and marker data in user-friendly and secure electronic database format with limited access.
F. Each Party shall be responsible for its compliance, and will comply, with all applicable laws, rules and regulations, including, without limitation, those relating to genetically modified organisms (to the extent the Program involves such organisms), and will obtain any and all permits or authorizations or proceed to any notifications which may be required by such laws, rules and regulations. When contributing sorghum germplasm for Program activities, the contributing Party will verify what the origin of the material is and inform the other Party in wr...
Research Management. 2.1 Conducts and manages clinical research in accordance with TGA, International Conference on Harmonisation (ICH) GCP, the NHMRC National Statement on Ethical Conduct in Research Involving Humans, HRECs and any other statutory and regulatory requirements and local institutional/hospital policies and procedures.
2.2 With the Head of Department, develops and executes a strategy for clinical research within the Medical Oncology department.
2.3 Leads the development, initiation, implementation and monitoring of new clinical research protocols.
Research Management. Development of ICFRE to improve the management and coordination of forestry research and extension through provision of: (i) staff training, studies and consultants’ services for the development of priority setting methodologies and a management information system; (ii) establishment of an extension support fund; and (iii) a new building and necessary computing and office equipment.
Research Management. During the Collaboration Term, a Joint Research Committee (JRC), composed of equal voting members from each Party, will oversee the Collaboration. The JRC will prioritize the research activities, review the progress of the Collaboration studies and make changes as it deems necessary to accomplish the Collaboration goals. The JRC will also determine the filing, prosecution, maintenance and cost allocation for the filing of patents covering Joint Inventions.
Research Management. Elan and Cytogen shall establish a ------------------- Supervisory Committee comprised of a designee of each of Cytogen and Elan, who shall initially be Xxxxxx X. XxXxxxx and Xxxxx Xxxxxx, or such other members of senior management as may be appointed by each party and approved by the other. The Supervisory Committee shall meet periodically and no less than once a quarter to review the overall conduct and performance of the Research Program. Each of the parties hereto shall provide to the Supervisory Committee monthly written reports and data on the status of their work under the Research Program and such other reports and information as may be requested by the Supervisory Committee from time to time to perform its duties hereunder. The Supervisory Committee may make such changes or modifications to the Research Plan as may be necessary to achieve the milestones set forth therein. Within thirty (30) days of the completion of the Research Program, as determined by the Supervisory Committee, Cytogen shall prepare and deliver to the Supervisory Committee a final written report which summarizes the data and findings arising from both its work and that of Elan under the Research Program. Elan agrees to cooperate and provide reasonable assistance to Cytogen in the preparation of such written report and Elan shall have the opportunity to review the final written report prior to its submission to the Supervisory Committee.
Research Management. The JMT shall also be responsible for the ------------------- day-to-day conduct and progress of the Research Program, including, without limitation:
(i) directing and administering the Research Program;
(ii) providing a forum for the exchange of scientific information among the scientists participating in the Research Program;
(iii) reviewing test reports derived from the research;
(iv) providing guidance to the Parties with respect to protection of Proprietary Technology;
(v) resolving matters involving scientific questions; and
Research Management. The Study will be coordinated by Xx. Xxxxxxx Xxxx at Interleukin and in collaboration with Dr. Xxxxxxxxxxx Xxxxx and Xx. Xxxxx Xxxxxxx at Xxxxxxxxx (each an “Investigator”). As described in the Protocol, Dr. Xxxxxxxxxxx Xxxxx is the Xxxxxxxxx Principal Investigator. Each Investigator will ensure that the Study is performed in accordance with the Protocol, and will use commercially reasonable efforts to ensure the accuracy of the Study Results.
